C12N 2710/24111
Orthopoxvirus
Official title: Orthopoxvirus, e.g. vaccinia virus, variola
C12N2710/24111 (Orthopoxvirus) appears on 978 US grants and 1,341 published applications in this corpus.
Search patents in C12N- Granted patents
- 978
- Published applications
- 1,341
- Assignees
- 555
- Inventors
- 1,948
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 2 | 0 |
| 1987 | 0 | 0 |
| 1988 | 2 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 6 | 0 |
| 1992 | 11 | 0 |
| 1993 | 12 | 0 |
| 1994 | 6 | 0 |
| 1995 | 10 | 0 |
| 1996 | 10 | 0 |
| 1997 | 14 | 0 |
| 1998 | 39 | 0 |
| 1999 | 23 | 0 |
| 2000 | 18 | 0 |
| 2001 | 21 | 4 |
| 2002 | 15 | 17 |
| 2003 | 18 | 55 |
| 2004 | 21 | 40 |
| 2005 | 18 | 43 |
| 2006 | 31 | 56 |
| 2007 | 20 | 49 |
| 2008 | 21 | 48 |
| 2009 | 27 | 69 |
| 2010 | 34 | 66 |
| 2011 | 48 | 73 |
| 2012 | 41 | 65 |
| 2013 | 45 | 66 |
| 2014 | 44 | 37 |
| 2015 | 44 | 50 |
| 2016 | 29 | 42 |
| 2017 | 30 | 51 |
| 2018 | 41 | 48 |
| 2019 | 31 | 60 |
| 2020 | 41 | 69 |
| 2021 | 35 | 65 |
| 2022 | 35 | 72 |
| 2023 | 29 | 69 |
| 2024 | 33 | 50 |
| 2025 | 44 | 39 |
| 2026 | 24 | 38 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2710/24141Use of virus, viral particle or viral elements as a vectorIndexing code674
- C12N 2710/24122New viral proteins or individual genes, new structural or functional aspects ofIndexing code222
- C12N 2710/24134Use of virus or viral component as vaccineIndexing code182
- C12N 2710/24132Use of virus as therapeutic agent, other than vaccineIndexing code148
- C12N 2710/24151Methods of production or purification of viral materialIndexing code85
- C12N 2710/24121Viruses as suchIndexing code81
- C12N 2710/24161Methods of inactivation or attenuationIndexing code60
- C12N 2710/24171Demonstrated in vivo effectIndexing code49
Recent patents
- Recombinant modified vaccinia virus (MVA) vaccine against coronavirus disease29 Sep 2026US 12,746,282 B2Bavarian Nordic A/S
- Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer18 Aug 2026US 12,708,653 B2Endeavor Health Clinical Operations
- HIV immunotherapy with no pre-immunization step18 Aug 2026US 12,709,753 B2American Gene Technologies International Inc.
- Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers4 Aug 2026US 12,698,512 B2City of Hope
- Prostate neoantigens and their uses28 Jul 2026US 12,692,513 B2Janssen Biotech, Inc.
- Tumor neoantigen vaccine system specifically marking heterologous protein, and use thereof8 Oct 2026US 2026/0306620 A1China Pharmaceutical University
- Rapid selection system for the generation of recombinant enveloped viruses8 Oct 2026US 2026/0308627 A1Probiogen AG
- Antibody Specifically Binding to CD276, Preparation Method Therefor and Use Thereof1 Oct 2026US 2026/0297196 A1Shanghai Sinobay Biotechnology Co., Ltd.
- Coronavirus vaccines inducing broad immunity against variants24 Sep 2026US 2026/0284179 A1Cambridge Enterprise Limited
- Monobodies selective to nras10 Sep 2026US 2026/0263609 A1New York University
Most cited
By later US patents
- Modified vaccinia virus298US 4,603,112 AHealth Research, Inc. · 1986
- Method for immunizing animals with synthetically modified vaccinia virus240US 4,722,848 AHealth Research, Inc. · 1988
- Vaccinia DNA172US 5,017,487 AHoffmann-La Roche Inc. · 1991
- Recombinant avipox virus and immunological use thereof151US 5,174,993 AHealth Research, Inc. · 1992
- Immunogenic composition comprising synthetically modified vaccinia virus144US 5,110,587 AHealth Research, Inc. · 1992